Article Text

Download PDFPDF
715 An 8 year retrospective review of gynae-oncology patients treated at a central London early phase trials unit
  1. Uma Mukherjee,
  2. Fatjon Dekaj,
  3. Angel Luis Orosco-Ttamina,
  4. Michael Flynn,
  5. Martin Forster and
  6. Rowan Miller
  1. University College London Hospital, London, UK

Abstract

Introduction/Background We describe the demographics and outcomes of patients with gynae-oncology malignancies treated on early phase trials (EPT) at the University College London Hospital (UCLH) phase 1 unit over an 8-year period.

Methodology Medical records were retrospectively analysed.

Results 96 women with gynae-oncology cancer (22 cervical, 19 endometrial, 50 ovarian, 5 vaginal/vulval) and an average age of 58 years (range 28 to 88 years) treated between 14/05/2015 and 12/10/2023 were identified. 63 were Caucasian, 7 Asian, 3 Black, 23 other/unknown and 92% spoke English as a first language. 59% of patents were referred from outside the Trust. There was a range of investigational medicinal product (IMP) types, including immunotherapy (33%) combination chemotherapy and small molecule inhibitor (19%), small molecule inhibitor monotherapy (15%), combination immunotherapy and targeted therapy (10%), cancer vaccine (3%)

Participants received a median of 2 lines of treatment before receiving EPT treatment (range 0 – 9). Following discontinuation on EPT, patients received a median of 0.87 further lines of therapy (range 0 -5). Median length of time between initial diagnosis and commencing EPT treatment was 32.1 months (range 4 – 196 months). Median Eastern Cooperative Oncology Group Performance status at time of referral was 1 (range 0–1).

At data cut off, 21 patients remain alive, of whom 6 continue to receive active EPT therapy. The median length of time on EPT was 3.6 months (range 0.5 - 26.9 months). Reasons for withdrawing from EPT included radiological disease progression (65%), toxicity (21%), clinical disease progression (7%), unknown/other (4%), completed trial (3%). The average survival time following discontinuation of treatment was 10.8 months (0.5 - 39 months).

Conclusion The EPT unit at UCLH has a strong background in treating patients with varied gynae-oncology malignancies across a range of IMP types. Future collection of quality-of-life data will also be important to further evaluate clinical benefit.

Disclosures The authors have no disclosures to make.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.